Follow us...


Search News Archives

News Channels


Coronavirus (COVID-19)


View Channel

New Laboratory Products


View Channel

Lab News


View Channel

Research & Case Studies


View Channel

Microscopy | Image Analysis


View Channel

Separation Science


View Channel



View Channel

Events | Webinars


View Channel

Conferences | Events
Avacta Life Sciences

Avacta Life Sciences

Avacta Life Sciences


Contact Avacta Life Sciences

If you have not logged into the website then please enter your details below.

All articles from Avacta Life Sciences

  Avacta and Cytiva collaborating on COVID-19 rapid test

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection. The World Health Organisation recently....


  Avacta Agrees Affimer Reagent Licensing Deal with New England Biolab

avactaAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswich MA, USA), a global leader in the discovery and production of enzymes for molecular biology applications, to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays. Avacta and NEB have been collaborating to develop Affimers to combine with NEB’s reagents....


  Avacta Group plc and Tufts University School of Medicine Collaborate to Develop Novel Class of Drug Conjugate

AvactaDrug conjugate combines Avacta’s Affimer technology with drug conjugates developed at Tufts. Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, Professor of Developmental...


  Avacta Group plc Announces Successful Outcome of “Gene Delivery” Collaboration with FIT Biotech

AvactaSustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits. Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its research collaboration with FIT Biotech Oy (FITBIO:FN Finland) has successfully completed a proof-of-concept study...


  Avacta and Oncosec to Collaborate on Innovative Gene Delivery of Therapeutic Affimers

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, are pleased to announce they have entered into a research collaboration to combine Avacta’s Affimer protein platform with OncoSec’s gene delivery technology ImmunoPulse®. The research programme will evaluate the benefits of delivering Affimer protein genes directly into tumors using the OncoSec technology....


  Avacta Group plc Announces Positive Outcome of Proof-of-Concept Study with Glythera and Follow-on Drug Development Partnership

avactaAvacta Group plc is pleased to announce that its initial study with Glythera Limited, the developer of next generation antibody drug conjugates, has concluded successfully. 

Following this study the two companies have agreed the terms of a licensing deal which will allow them to develop drug conjugates using the combined technologies.  The detailed terms of the license have not been disclosed but Avacta would receive development milestone payments and royalties


  Avacta Initiates Gene Therapy Research Collaboration with FIT Biotech Oy

Collaboration to assess the benefits of combining Affimer technology with FIT Biotech’s gtGTU platform

avactaAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce it has initiated a research collaboration with FIT Biotech Oy (FITBIO:FN Finland) to assess the effectiveness of developing gene therapies using Avacta’s Affimer technology combined....


  Top Three Global Diagnostics Company takes Exclusive Rights to Several of Avacta’s Affimer Reagents

Important value inflection point validating commercial potential of Affimer technology and Company's business model

avactaAvacta Group plc, the developer of Affimer® biotherapeutics and research reagents, is pleased to report that an evaluation of the Affimer technology by a large, global diagnostics developer has concluded successfully and that the third party has taken exclusive rights to several Affimer reagents....


  Excellent Results for Affimer Technology in Industry-Standard Immunogenicity Study Using Human Samples

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to report that the first major immunogenicity study of Affimer technology using human ex-vivo samples has concluded successfully with a range of Affimer proteins shown to have low immunogenicity comparable with the marketed antibody Avastin®.

avactaUnwanted immunogenicity occurs when a patient has an immune response to a drug which can lead to reduced effectiveness of the drug and possibly lead to serious adverse side effects. It is therefore essential that a new drug platform, such as Affimer technology, is shown not to cause a significant intrinsic immunogenic response....


  World-Leading Cancer Stem Cell Expert Joins Avacta Scientific Advisory Board

Appointment of Professor Gerard Evan further supports Affimer immuno-oncology therapeutics programme

AvactaAvacta Group plc, the developer of Affimer® biotherapeutics and research reagents, has announced it has appointed Professor Gerard Evan, FRS, to its therapeutics Scientific Advisory Board. Professor Evan brings world-leading expertise in immuno-oncology and cancer stem cell research...


  Avacta Announces CAR-T Cell Therapy Research Collaboration with Major US Cancer Centre

Avacta Group plc announces a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta’s Affimer technology in novel CAR-T cell-based immunotherapy.

AvactaCAR-T immunotherapy is a form of cancer treatment in which the patient’s own immune system T cells are modified to give them greater potency with which to attack cancer cells .Treatments using these engineered immune cells have generated promising responses in patients with advanced cancers and CAR-T immunotherapy has become an intense area of research, clinical development and investment.


  Positive Results from First Preclinical in-vivo Studies of Affimer Therapeutics

Affimer PD-L1 inhibitor significantly reduces tumour growth in mouse model

AvactaAvacta Group plc, the developer of Affimer® biotherapeutics and research reagents, is pleased to announce positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules. The results meaningfully de-risk the development of the technology as a therapeutic platform; demonstrating that Affimer molecules possess good drug-like properties in terms of efficacy, serum half-life and tolerability....


  Avacta Expands into New Facilities in Cambridge and Wetherby

Expansion provides significant increase in laboratory space

avactaAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, today announced it has opened two new facilities, in Cambridge and Wetherby, Yorkshire. The new buildings almost double the Company’s overall footprint, which increases from 9,500 to 18,500 sq ft, including new state-of-the-art laboratory facilities....


  Avacta and Leeds University Awarded ÂŁ3.8m Medical Research Council Funding to Develop new Diagnostic Tests

Collaboration to develop rapid tests to differentiate between viral and bacterial infections, and differentiate bacterial strains


Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that a collaborative development programme with Leeds University has been awarded a £3.8 million grant by the Medical Research Council to develop novel, rapid diagnostic tools incorporating Affimer reagents, to differentiate between viral and bacterial infections, and differentiate bacterial strains....


  Avacta and Glythera Announce Collaboration to Develop Novel, Potentially Highly Potent, Drug Class

Avacta Group plc and Glythera Limited announce that they have established a collaboration to evaluate the use of Glythera’s PermaLink™ conjugation chemistry in combination with Avacta’s Affimer technology with the aim of developing a new class of highly targeted bio-therapeutics as a superior alternative to the established class of antibody drug conjugates (ADCs).


ADCs use an antibody to which a toxin/chemotherapy payload is chemically attached for targeted delivery to a tumour. Over 50 ADCs are currently in clinical development; of these, approximately a quarter are in Phase II or Phase III. The market is estimated to be worth around $1bn today from two approved compounds and is expected to be worth $10bn annually by 2024.


  Avacta Rapidly Generates Affimer Binders for Zika Virus Diagnostics

Avacta Group plc has announced it has identified three Affimer proteins capable of binding to a recombinant form of a secreted Zika virus NS1 protein (Non-Structural protein 1), which is diagnostic of Zika virus infection at the early, acute stage.

AvactaThese Affimer binders were identified and characterised within just thirteen weeks of receiving the virus target and have the potential to be developed into new rapid point-of-care diagnostic tests for Zika infection.


  Avacta and Mologic Enter Research and Product Development Collaboration Agreement

Avacta’s Affimer technology will be used to develop rapid lateral flow diagnostics for clinical applications

AvactaAvacta Group plc (AIM: AVCT) the developer of Affimer® biotherapeutics and research reagents, and Mologic, a specialist diagnostic development company, today announced they have formed a collaborative partnership to develop diagnostic tests against multiple targets of clinical interest for point of care (POC) testing, using Avacta’s Affimer technology. As stated at the time of Avacta’s interim results, establishing commercial relationships in the POC testing market is one of the Company’s key strategic objectives....


  Avacta Life Sciences Unveils Custom Seven Week Affimer Service to Revolutionise Life Sciences

Avacta Life Sciences, the global provider of high quality reagents for life sciences, has launched a ground breaking new website for it’s Affimer technology.

avactaAffimers are a new alternative to antibodies and aptamers. Based on a small protein scaffold, they can be engineered to bind with high specificity and affinity to a wide range of protein targets. Affimers can be used for a wide range of applications in diagnostics, drug / biomarker discovery, biotech research & development and in developing therapeutics. To provide a world-class user experience for customers, Avacta’s new website has been...


  Avacta extends Optim 2 product family for even greater measurement flexibility

Avacta’s Optim® 2 platform is an innovative analytical instrument designed to probe multiple protein stability indicating parameters at high speed using ultra-low sample volumes.

Optim® 2Developed to reduce the time and cost of therapeutic protein preformulation studies, the functionality of this compact instrument family has now been further enhanced with the addition of two new models. The Optim 375 is intended for the investigation of complex mixtures of membrane proteins, using an additional 375 nm laser source to provide a novel stability screen based on the chemical reactivity of cysteine residues....


  Avacta Lifes Sciences Launches Affimers, Alternative to Antibodies

Avacta Life Sciences is investing ÂŁ10m in the launch of Affimers, the engineered alternative to antibodies.

Affimers are small single domain proteins that are engineered to solve several significant problems faced by commercial and academic researchers using antibodies. They open up areas of research where toxicity prevents the development of antibodies and they have a 90% success rate in matching to targets in a process that takes 7 weeks rather than 7 to 10 months....





Media Partners